Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EQS-Adhoc : Polyphor provides final update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer

08/03/2021 | 01:01pm EDT

EQS Group-Ad-hoc: Polyphor AG / Key word(s): Study results Polyphor provides final update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer 03-Aug-2021 / 19:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. -----------------------------------------------------------------------------------------------------------------------

Allschwil, Switzerland, August 3, 2021

Polyphor provides final update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer

- Primary endpoint of the study progression free survival (PFS) was not met

- Pre-specified interim analysis of overall survival (OS) showed no statistically significant differences between study groups Polyphor AG (SIX: POLN) today announced that its global Phase III FORTRESS study, evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did also not meet its primary endpoint. As communicated, the analysis was conducted following the company's decision to initiate the closure of the FORTRESS study.

The FORTRESS study investigates the efficacy and safety of the combination of balixafortide and eribulin versus eribulin monotherapy in patients with HER2 negative metastatic breast cancer with progressive disease after one to four lines of chemotherapy. Progression free survival (PFS) is the key primary endpoint of the study. 432 patients were included in the FORTRESS study, thereof 348 having had at least two lines of prior chemotherapy, a prespecified subgroup of the study.

The study did not meet its primary endpoint of PFS in the overall population (n=432 patients): HR=1.10 (0.85, 1.41); p=0.445; median PFS: 3.5 m (B+E) vs. 4.0 m (E) and also not in the patients with at least 2 prior lines of chemotherapy according to the assessment of the blinded independent review committee (n=348 patients): HR=1.07 (0.81, 1.41); p= 0.6158; median PFS: 3.5 m (B+E) vs. 4.0 m (E). Investigator assessment of PFS was consistent with the independent review committee analysis (HR=0.99 for the overall population and HR=1.05 for the > second line population).

At the time of the PFS analysis, a pre-specified interim analysis of overall survival (OS) was conducted as well. There were no statistically significant differences for survival in the overall population (230 events): HR=1.08 (0.71,1.63); p=0.5897; median OS: 10.9 m (B+E) vs. 11.7 m (E) or in the > second line population (181 events): HR=1.08 (0.66, 1.77); p=0.6126; median OS: 11.0 m (B+E) vs. 11.2 m (E).

The analysis of the safety and tolerance of balixafortide in combination with eribulin in the FORTRESS study was consistent with the previously reported safety profile with a numerically higher number of patients having had serious adverse events (28.4% B+E vs. 26.5% E) or adverse events of a grade 3 or higher severity (68.3% B+E vs. 63.7% E).

Based on these results, the FORTRESS study will be closed and the pre-specified secondary efficacy analysis of OS after reaching 284 events in the overall population will not be performed.

"We are disappointed with the results of the FORTRESS study given the high unmet medical need for patients with advanced breast cancer," says Frank Weber, CMO of Polyphor. "As previously communicated, we will now close the study. We thank all the patients, investigators and healthcare professionals as well as our employees for their active participation in this study."

As recently announced, the board of directors has extended the period for strategic evaluation of all options for the future of the Company by not later than end of August.

About the FORTRESS study The FORTRESS study (POL6326-009) is an international, multicenter, randomized active-controlled, open-label Phase III trial which investigates the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, locally recurrent or metastatic breast cancer. The study had randomized 432 patients with HER2 negative MBC with at least 344 patients receiving third or subsequent line and 88 patients receiving second line chemotherapy.

About balixafortide Balixafortide (POL6326) is a potent, specific, and highly selective antagonist of the chemokine receptor CXCR4, a G-protein coupled receptor (GPCR) that regulates the trafficking and homing of both cancer cells and cells of the patient's immune system.

For further information please contact: For Investors: For Media: Hernan Levett Dr. Stephan Feldhaus Chief Financial Officer Feldhaus & Partner Polyphor Ltd. +41 79 865 92 56 +41 61 567 16 00 feldhaus@feldhaus-partner.ch IR@polyphor.com

About Polyphor Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing novel molecules in oncology and antimicrobial resistance leveraging the company's proprietary macrocyclic peptide technology platform. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. ----------------------------------------------------------------------------------------------------------------------- End of ad hoc announcement ----------------------------------------------------------------------------------------------------------------------- Language: English Company: Polyphor AG

Hegenheimermattweg 125

4123 Allschwil

Switzerland Phone: +41 61 567 1600 Fax: +41 61 567 1601 E-mail: info@polyphor.com Internet: www.polyphor.com ISIN: CH0106213793 Valor: POLN Listed: SIX Swiss Exchange EQS News ID: 1223823 End of Announcement EQS Group News Service -------------

1223823 03-Aug-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1223823&application_name=news

(END) Dow Jones Newswires

August 03, 2021 13:00 ET (17:00 GMT)

All news about POLYPHOR AG
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/15La Commission des OPA constate l'absence d'obligation de présenter une offre publique d..
DJ
10/15Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer ..
DJ
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor publishes invitation to Extraordinary General Meeting and announces financial ..
DJ
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
More news
Financials
Sales 2021 1,00 M 1,09 M 1,09 M
Net income 2021 -41,4 M -45,1 M -45,1 M
Net Debt 2021 76,8 M 83,7 M 83,7 M
P/E ratio 2021 -0,46x
Yield 2021 -
Capitalization 21,2 M 23,1 M 23,1 M
EV / Sales 2021 98,0x
EV / Sales 2022 5,64x
Nbr of Employees 52
Free-Float 82,3%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 1,72 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-78.90%23
CSL LIMITED5.58%102 349
WUXI BIOLOGICS (CAYMAN) INC.14.30%64 102
SAMSUNG BIOLOGICS CO.,LTD.8.72%50 698
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.72%38 185